Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure.

Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure.
Author Information (click to view)

Verbrugge FH,


Verbrugge FH, (click to view)

Verbrugge FH,

Advertisement

Current heart failure reports 2017 06 24() doi 10.1007/s11897-017-0340-1
Abstract
PURPOSE OF REVIEW
This review aims to summarize the evidence on cardiovascular risks and benefits of glucose-lowering drugs in diabetic patients, with a particular focus on the role of sodium-glucose transporter-2 (SGLT-2) inhibitors and their promising potential as a heart failure treatment.

RECENT FINDINGS
The SGLT-2 inhibitor empagliflozin has emerged as the first glucose-lowering drug to lower cardiovascular mortality in diabetes with an unprecedented 38% relative risk reduction. In addition, empagliflozin significantly reduced the rate of heart failure admissions with 35% when compared to placebo in diabetic patients with established atherosclerosis. SGLT-2 inhibitors should be considered as a first-line drug to achieve glycemic control in diabetic patients at high risk for cardiovascular diseases and heart failure in particular. As SGLT-2 inhibitors target different pathophysiological pathways in heart failure, they might even be considered in the broader population without diabetes, but this remains the topic of further study.

Submit a Comment

Your email address will not be published. Required fields are marked *

16 + 18 =